JAK of all trades: Ruxolitinib as a new therapeutic option for CML patients

Leuk Res. 2018 Dec:75:71-72. doi: 10.1016/j.leukres.2018.10.010. Epub 2018 Oct 24.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Janus Kinase 2 / antagonists & inhibitors
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Nitriles
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazoles / therapeutic use*
  • Pyrimidines

Substances

  • Antineoplastic Agents
  • Nitriles
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib
  • JAK2 protein, human
  • Janus Kinase 2